The effect of trans-tenon triamcinolone acetonide injection on intraocular pressure in diffuse diabetic macular edema

Amaç: Diffüz diyabetik maküler ödemli hastalarda trans-Tenon retrobulber triamsinolon asetonid (TTTA) enjeksiyonu sonrası göziçi basıncı değerlendirildi. Hastalar ve Yöntemler: Bu retrospektif çalışmada diffüz diyabetik ödem tanısı konan 21 hastanın (12 kadın, 9 erkek; ort. yaş 63.7±6.92; dağılım 49-77) 30 gözüne tek doz 20 mg TTTA enjeksiyonu yapıldı. Göziçi basınçları, enjeksiyon öncesinde ve enjeksiyondan bir hafta, bir ay ve üç ay sonra değerlendirildi. Bulgular: Enjeksiyon sonrası göziçi basınç artışı sadece birinci haftada meydana geldi. Göziçi basınç artışları, topikal antiglokomatöz tedavi ile normal değerlere döndü. Birinci ve üçüncü ayda görme keskinliğinde gözlenen artış anlamlı bulundu. Sonuç: Diffüz diyabetik ödemde tek doz 20 mg TTTA enjeksiyonunun güvenli ve etkili bir tedavi olduğu sonucuna varıldı.

Anahtar Kelimeler:

Görme keskinliği, Oküler hipertansiyon, Geriyedönük çalışma, Maküla ödemi, Diabetik retinopati, Triamsinolon asetonit

Diffüz diyabetik maküler ödemde trans-tenon triamsinolon asetonid enjeksiyonu’nun göziçi basıncı üzerine etkisi

Objectives: We evaluated the intraocular pressure (IOP) after trans-Tenon retrobulbar injections of triamcinolone acetonide (TTTA) in patients with with diffuse diabetic macular edema. Patients and Methods: We retrospectively reviewed 30 eyes of 21 consecutive patients (12 females, 9 males; mean age 63.7±6.92 years; range 49 to 77 years) who received a single dose of 20 mg TTTA injection for diffuse diabetic macular edema. Intraocular pressures were evaluated before and one week, one month, and three months after the injection. Results: Elevation of the IOP occurred only during the first week after TTTA injections. These rises returned to normal values with topical antiglaucoma medications. Improvements in visual acuity were significant at one month and three months. Conclusion: It was concluded that single-dose 20 mg TTTA injection was a safe and effective treatment in diffuse diabetic macular edema.

Keywords:

Visual Acuity, Ocular Hypertension, Retrospective Studies, Macular Edema, Diabetic Retinopathy, Triamcinolone Acetonide,

PDF

___

1) Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-4.

2) Koga T, Mawatari Y, Inumaru J, Fukushima M, Tanihara H. Trans-Tenon’s retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy. Graefes Arch Clin Exp Ophthalmol 2005;243:1247-52.

3) Wada M, Ogata N, Minamino K, Koriyama M, Higuchi A, Matsumura M. Trans-Tenon’s retrobulbar injection of triamcinolone acetonide for diffuse diabetic macular edema. Jpn J Ophthalmol 2005;49:509-15.

4) Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma 1995;4:354-369.

5) Hirooka K, Shiraga F, Tanaka S, Baba T, Mandai H. Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone. Jpn J Ophthalmol 2006;50:235-8.

6) Javadzadeh A. The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series. BMC Ophthalmol 2006;6:15.

7) Cardillo JA, Melo LA Jr, Costa RA, Skaf M, Belfort R Jr, Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-63.

8) Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.

9) Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, Fontanarosa J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.

10) Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin Experiment Ophthalmol 2006;34:27-32.

11) Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-24.

12) Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-9.

13) Moshfeghi DM, Kim BY, Kaiser PK, Sears JE, Smith SD. Appositional suprachoroidal hemorrhage: a case-control study. Am J Ophthalmol 2004;138:959-63.

14) Dal Canto AJ, Downs-Kelly E, Perry JD. Ptosis and orbital fat prolapse after posterior sub-Tenon’s capsule triamcinolone injection. Ophthalmology 2005; 112:1092-7.

15) Ozkiriş A, Erkiliç K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-8.

16) Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.

17) Ohguro N, Okada AA, Tano Y. Trans-Tenon’s retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2004;242:444-5.

18) Entezari M, Ahmadieh H, Dehghan MH, Ramezani A, Bassirnia N, Anissian A. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial.Eur J Ophthalmol 2005;15:746-50.